Trial Profile
Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukaemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Methotrexate; Rituximab; Vincristine
- Indications B-cell leukaemia; Burkitt's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 17 Jun 2021 Results of propensity score analysis in Philadelphia chromosome negative acute lymphoblastic leukemia, published in the Cancer.
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology